Tristel PLC
LSE:TSTL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
350
500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Tristel PLC
Tristel PLC
EPS (Diluted)
Tristel PLC
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tristel PLC
LSE:TSTL
|
EPS (Diluted)
£0
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
21%
|
|
|
Abingdon Health PLC
LSE:ABDX
|
EPS (Diluted)
£0
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ConvaTec Group PLC
LSE:CTEC
|
EPS (Diluted)
$0
|
CAGR 3-Years
0%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Inspecs Group PLC
LSE:SPEC
|
EPS (Diluted)
£0
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Advanced Medical Solutions Group PLC
LSE:AMS
|
EPS (Diluted)
£0
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-2%
|
|
|
Cambridge Nutritional Sciences PLC
LSE:CNSL
|
EPS (Diluted)
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tristel PLC
Glance View
Tristel Plc engages in the design, development, manufacture, and sale of infection control, contamination control and hygiene products. The company is headquartered in Snailwell, Cambridgeshire and currently employs 189 full-time employees. The company went IPO on 2005-06-01. The Company’s technology is a chlorine dioxide formulation used by hospitals for the high-level disinfection of medical devices and the sporicidal disinfection of environmental surfaces. The Company’s segments include Hospital medical device decontamination and Hospital environmental surface disinfection. The firm manufactures and sells medical device decontamination products that are used primarily for infection control in hospitals. The firm also manufactures and sells hospital environmental surface disinfection products. The Tristel brand offers airway management, cardiology, ear, nose and throat, ophthalmology, endoscopy, phlebotomy, surfaces, ultrasound, urology, and women's health. The Crystel brand offers pharmaceutical, cosmetic and toiletry (PCT), cleanroom disinfectants and laboratory disinfectants. The company markets its products under the Tristel, Anistel, and Crystel brands.
See Also
What is Tristel PLC's EPS (Diluted)?
EPS (Diluted)
0.1
GBP
Based on the financial report for Dec 31, 2023, Tristel PLC's EPS (Diluted) amounts to 0.1 GBP.
What is Tristel PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
21%
Over the last year, the EPS (Diluted) growth was 86%. The average annual EPS (Diluted) growth rates for Tristel PLC have been 9% over the past three years , 10% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet
